Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
USERS' SCORE
Moderately Good
Based on 25 Reviews
7.6
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Vitamin K2 (as Menaquinone-4) (MK-4)
100 mcg
**
Alfalfa Powder (Aerial Parts)
250 mg
**
Top Medical Research Studies
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
Most Useful Reviews
9
Clot prevention
6 people found this helpful
Vitamin K2 stimulates proteins that remove excess calcium from veins and arteries, crucial for protecting against clots. Atherosclerosis, often linked to calcium deposits, can lead to cardiovascular disease, making K2 an important supplement.
Read More
9
Cardiac health benefits
4 people found this helpful
I ordered Vitamin K2 to prevent osteoporosis, taking it with Vitamin D3. K2 fixes calcium in bones and averts cardiovascular disease by preventing calcium deposits in blood vessels. High-quality product, with small capsules that are easy to swallow.
Read More
9
Bone health importance
2 people found this helpful
Vitamin K2 is crucial for protein synthesis and strengthens bones. It redirects calcium from blood to bone tissue, influencing blood density and clotting. Especially important for children and pregnant women, K2's deficiency can harm skeletal development and health.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
- All Researches
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Read More
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
7
Atrial fibrillation treatment effectiveness confirmed
We explored how closely real-world patients with atrial fibrillation matched the results from major trials using apixaban and rivaroxaban compared to vitamin K antagonists. By tracking patients from the GARFIELD-AF registry, we observed that these real-life outcomes on stroke prevention, bleeding, and mortality closely mirrored those of the original trials. The study found that while the real-world patients had lower cardiovascular risks, the efficacy and safety of the treatments remained strong and comparable. This demonstrates that the findings from the ARISTOTLE and ROCKET AF trials are relevant in everyday clinical settings.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 25 Reviews
7.6
- All Reviews
- Positive Reviews
- Negative Reviews
9
Clot prevention
6 people found this helpful
Vitamin K2 stimulates proteins that remove excess calcium from veins and arteries, crucial for protecting against clots. Atherosclerosis, often linked to calcium deposits, can lead to cardiovascular disease, making K2 an important supplement.
Read More
9
Cardiac health benefits
4 people found this helpful
I ordered Vitamin K2 to prevent osteoporosis, taking it with Vitamin D3. K2 fixes calcium in bones and averts cardiovascular disease by preventing calcium deposits in blood vessels. High-quality product, with small capsules that are easy to swallow.
Read More
9
Bone health importance
2 people found this helpful
Vitamin K2 is crucial for protein synthesis and strengthens bones. It redirects calcium from blood to bone tissue, influencing blood density and clotting. Especially important for children and pregnant women, K2's deficiency can harm skeletal development and health.
Read More
9
Essential for health
1 people found this helpful
As someone with a family history of cardiovascular disease, I find K-2 vital for my health and fitness regimen at 76 years old. It is an essential part of my nutrition and workout programme, helping maintain my outstanding health.
Read More
9
Regulates blood clotting
Vitamin K2 is vital for regulating blood clotting and preventing excessive bleeding and fractures from impaired bone health. This supplement not only assists with calcium assimilation but also reinforces my cardiovascular health, boosts immunity, and improves overall well-being. The capsule size enhances usability.
Read More
Frequently Asked Questions
9
Improved cardiovascular health
I purchased this product for bone and cardiovascular health and was very pleased. It's a vegetarian option that suits my diet. After a month of use, I've noticed positive changes. The heaviness in my legs has significantly decreased, and my general well-being has improved. The dosage of 100 mcg is optimal for daily intake. I intend to continue using it as vitamin K2 is crucial for calcium absorption. I recommend it to anyone prioritising their health!
9
Reduces cardiovascular disease
Vitamin K2 in the mk4 formula, taken with vitamin D3, aids calcium absorption into bones and prevents cardiovascular disease by protecting blood vessels from calcification. The price-quality ratio is excellent compared to other brands. Don't overlook vitamin K2, especially as it can reduce the risk of fractures and various diseases, including cancer and inflammation. Combined with D3 and fats, it provides great health benefits. Wishing you health and resilience!
7.5
Calcium metabolism
2 people found this helpful
Vitamin K2 is vital for calcium metabolism and reduces cardiovascular disease risk. I take it with calcium and Vitamin D for optimal health.
9
Cardiac health benefits
4 people found this helpful
I ordered Vitamin K2 to prevent osteoporosis, taking it with Vitamin D3. K2 fixes calcium in bones and averts cardiovascular disease by preventing calcium deposits in blood vessels. High-quality product, with small capsules that are easy to swallow.
6
Osteoporosis reduction
6 people found this helpful
Vitamin K2 reduces osteoporosis risk by directing calcium into bones. It promotes wound healing and prevents arterial calcification, benefiting cardiovascular health. Additionally, it supports the synthesis of critical nerve sheath components, essential for brain function. I recommend purchasing it!
7.5
Energy boost
2 people found this helpful
This Vitamin K2 is effective and affordable. After using it, I noticed improved immunity and vitality. I recommend it highly for its benefits, especially when taken with Vitamin D3 for better calcium metabolism, reducing cardiovascular disease risk.
7.5
Heart protection
2 people found this helpful
I regularly take Vitamin D3 alongside K-2 to prevent calcium deposits in blood vessels, protecting my cardiovascular system while directing calcium to bones. This is an essential product for everyone.
7.5
Convenient cardiovascular aid
Vitamin K-2, at 100 mcg in 100 vegetarian capsules, supports both bone and cardiovascular health. It's convenient for those looking for a natural vitamin K supplement.
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
References
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. doi:10.1007/s11739-025-03922-6
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. doi:10.36660/abc.20240147
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. doi:10.1007/s11239-025-03067-5
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. doi:10.1161/JAHA.124.038834
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002966
